Akero Therapeutics Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Hello, and welcome to the H.C. Wainwright 5th Annual NASH Investor Conference. My name is Ed Arce, and I'm one of the senior biotech analysts here at H.C. Wainwright, and I'm very pleased to have with us our next presenting company, Akero Therapeutics. And representing the company is Dr. Tim Rolph. He is the Co-Founder and Chief Scientific Officer of Akero. Tim, welcome.
Delighted to be with you, Ed.
Great. Very glad to have you with us. Let's jump right in. Akero is a company well known to many investors that are following the space. But let's start off by going over the key takeaways from your prior main study, the BALANCED Phase 2a study in F2/F3 patients, including of course the profound liver fat reductions that you saw in that study. And I should mention that as well the full results of that study have now recently been published in the top-tier
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |